Xiaflex: Phase II started
BioSpecifics Technologies started a double-blind, U.S. Phase II trial of Xiaflex in 20 adult patients with >=2 benign lipomas of similar size. Patients will have 1 lipoma treated with Xiaflex, while the other will receive placebo.
Auxilium has exclusive, worldwide rights from BioSpecifics to develop and commercialize Xiaflex for Dupuytren’s disease, Peyronie’s disease, frozen shoulder syndrome (adhesive capsulitis) and cellulite, and has an exclusive option to license development and commercialization rights to include the treatment of lipoma based on data from the Phase II trial. Auxilium would be responsible for future development costs if it exercises the option, and BioSpecifics would be eligible for an opt-in payment and undisclosed milestone and royalty payments. ...